To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.

Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.

To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.

Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.